Journal article

iPSC- and mesenchymoangioblast-derived mesenchymal stem cells provide greater protection against experimental chronic allergic airways disease compared with a clinically used corticosteroid

Simon G Royce, WeiYi Mao, Rebecca Lim, Kilian Kelly, Chrishan S Samuel

FASEB JOURNAL | FEDERATION AMER SOC EXP BIOL | Published : 2019

Abstract

The airway remodeling (AWR) associated with chronic allergic airways disease (AAD)/asthma contributes to irreversible airway obstruction. This study compared and combined the antiremodeling and other effects of induced pluripotent stem cell and mesenchymoangioblast-derived mesenchymal stem cells (MCA-MSCs) with the corticosteroid dexamethasone (Dex) in experimental chronic AAD/asthma. Female BALB/c mice subjected to 11 wk of ovalbumin (Ova)-induced chronic AAD were intranasally administered MCA-MSCs (1 × 106 cells/mouse; once weekly on wk 10 and 11), Dex (0.5 mg/ml; once daily for 2 wk), or both combined. MCA-MSC detection and changes in airway inflammation (AI), AWR, and airway hyperrespons..

View full abstract

Grants

Awarded by National Health and Medical Research Council (NHMRC) of Australia Senior Research Fellowship


Funding Acknowledgements

The authors acknowledge the facilities and technical assistance of the Monash Histology Platform (Monash University). This work was supported by a National Health and Medical Research Council (NHMRC) of Australia Senior Research Fellowship (GNT1041766 to C.S.S.) and Cynata Therapeutics Ltd. (Carlton, VIC, Australia) funding (to C.S.S. and S.G.R.). K.K. is an employee and shareholder of Cynata Therapeutics, but was not involved with performing the experiments or analysis of data.